Shilpa Medicare Limited

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:01:00 2024-06-05 EDT			5-day change	1st Jan Change
490 ^INR	+10.71%		+3.80%	+48.31%

05-24	Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024
05-23	Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Shilpa Medicare Limited Appoints Alpesh Dalal as Chief Financial Officer

May 31, 2021 at 05:58 am

Shilpa Medicare Limited at its board meeting held on May 31, 2021 approved the appointment of Mr. Alpesh Dalal as Chief Financial Officer of the company.

Latest news about Shilpa Medicare Limited

Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024	05-24
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-23	CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	05-14	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	04-18	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	04-17	MT
Shilpa Medicare Gets Board Nod to Launch QIP	04-09	MT
Shilpa Medicare's Life Science Arm Names CEO	03-28	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	03-01	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	02-26	MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024	02-12
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	01-19	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-10	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	11-02	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	23-10-11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	23-09-04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	23-09-04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	23-09-01	CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	23-08-25	MT
Transcript : Shilpa Medicare Limited, Q1 2024 Earnings Call, Aug 11, 2023	23-08-11
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries	23-08-08	CI
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections	23-07-31	MT
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India	23-06-29	CI
Shilpa Medicare to Raise Up to INR3.25 Billion from Rights Issue	23-06-23	MT

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHILPA MEDICARE LIMITED	+48.31%	460M
ELI LILLY AND COMPANY	+42.83%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-5.70%	356B
MERCK & CO., INC.	+18.06%	326B
ABBVIE INC.	+4.63%	286B
ASTRAZENECA PLC	+17.72%	246B
NOVARTIS AG	+10.76%	213B
ROCHE HOLDING AG	-3.07%	213B
PFIZER, INC.	+2.43%	167B

Other Pharmaceuticals